These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 15958580)

  • 1. Antitumor activity of rapamycin in a transgenic mouse model of ErbB2-dependent human breast cancer.
    Liu M; Howes A; Lesperance J; Stallcup WB; Hauser CA; Kadoya K; Oshima RG; Abraham RT
    Cancer Res; 2005 Jun; 65(12):5325-36. PubMed ID: 15958580
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ErbB2 increases vascular endothelial growth factor protein synthesis via activation of mammalian target of rapamycin/p70S6K leading to increased angiogenesis and spontaneous metastasis of human breast cancer cells.
    Klos KS; Wyszomierski SL; Sun M; Tan M; Zhou X; Li P; Yang W; Yin G; Hittelman WN; Yu D
    Cancer Res; 2006 Feb; 66(4):2028-37. PubMed ID: 16489002
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antiangiogenic potential of the Mammalian target of rapamycin inhibitor temsirolimus.
    Del Bufalo D; Ciuffreda L; Trisciuoglio D; Desideri M; Cognetti F; Zupi G; Milella M
    Cancer Res; 2006 Jun; 66(11):5549-54. PubMed ID: 16740688
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rapamycin inhibits growth of premalignant and malignant mammary lesions in a mouse model of ductal carcinoma in situ.
    Namba R; Young LJ; Abbey CK; Kim L; Damonte P; Borowsky AD; Qi J; Tepper CG; MacLeod CL; Cardiff RD; Gregg JP
    Clin Cancer Res; 2006 Apr; 12(8):2613-21. PubMed ID: 16638874
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Downregulation of Notch pathway by a gamma-secretase inhibitor attenuates AKT/mammalian target of rapamycin signaling and glucose uptake in an ERBB2 transgenic breast cancer model.
    Efferson CL; Winkelmann CT; Ware C; Sullivan T; Giampaoli S; Tammam J; Patel S; Mesiti G; Reilly JF; Gibson RE; Buser C; Yeatman T; Coppola D; Winter C; Clark EA; Draetta GF; Strack PR; Majumder PK
    Cancer Res; 2010 Mar; 70(6):2476-84. PubMed ID: 20197467
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination strategy targeting the hypoxia inducible factor-1 alpha with mammalian target of rapamycin and histone deacetylase inhibitors.
    Verheul HM; Salumbides B; Van Erp K; Hammers H; Qian DZ; Sanni T; Atadja P; Pili R
    Clin Cancer Res; 2008 Jun; 14(11):3589-97. PubMed ID: 18519793
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibitory effect of rapamycin on corneal neovascularization in vitro and in vivo.
    Kwon YS; Hong HS; Kim JC; Shin JS; Son Y
    Invest Ophthalmol Vis Sci; 2005 Feb; 46(2):454-60. PubMed ID: 15671269
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HER-2/neu overexpression increases the viable hypoxic cell population within solid tumors without causing changes in tumor vascularization.
    Dragowska WH; Warburton C; Yapp DT; Minchinton AI; Hu Y; Waterhouse DN; Gelmon K; Skov K; Woo J; Masin D; Huxham LA; Kyle AH; Bally MB
    Mol Cancer Res; 2004 Nov; 2(11):606-19. PubMed ID: 15561777
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment with farnesyl-protein transferase inhibitor induces regression of mammary tumors in transforming growth factor (TGF) alpha and TGF alpha/neu transgenic mice by inhibition of mitogenic activity and induction of apoptosis.
    Nørgaard P; Law B; Joseph H; Page DL; Shyr Y; Mays D; Pietenpol JA; Kohl NE; Oliff A; Coffey RJ; Poulsen HS; Moses HL
    Clin Cancer Res; 1999 Jan; 5(1):35-42. PubMed ID: 9918200
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Estrogenic promotion of ErbB2 tyrosine kinase activity in mammary tumor cells requires activation of ErbB3 signaling.
    Liu B; Ordonez-Ercan D; Fan Z; Huang X; Edgerton SM; Yang X; Thor AD
    Mol Cancer Res; 2009 Nov; 7(11):1882-92. PubMed ID: 19861407
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Macrophage inhibitory cytokine-1 activates AKT and ERK-1/2 via the transactivation of ErbB2 in human breast and gastric cancer cells.
    Kim KK; Lee JJ; Yang Y; You KH; Lee JH
    Carcinogenesis; 2008 Apr; 29(4):704-12. PubMed ID: 18258606
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of hypoxia-related gene expression in sarcomas and effect of hypoxia on RNA interference of vascular endothelial cell growth factor A.
    Detwiller KY; Fernando NT; Segal NH; Ryeom SW; D'Amore PA; Yoon SS
    Cancer Res; 2005 Jul; 65(13):5881-9. PubMed ID: 15994966
    [TBL] [Abstract][Full Text] [Related]  

  • 13. p130Cas as a new regulator of mammary epithelial cell proliferation, survival, and HER2-neu oncogene-dependent breast tumorigenesis.
    Cabodi S; Tinnirello A; Di Stefano P; Bisarò B; Ambrosino E; Castellano I; Sapino A; Arisio R; Cavallo F; Forni G; Glukhova M; Silengo L; Altruda F; Turco E; Tarone G; Defilippi P
    Cancer Res; 2006 May; 66(9):4672-80. PubMed ID: 16651418
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sirolimus inhibits human pancreatic carcinoma cell proliferation by a mechanism linked to the targeting of mTOR/HIF-1 alpha/VEGF signaling.
    Wang Y; Zhao Q; Ma S; Yang F; Gong Y; Ke C
    IUBMB Life; 2007 Nov; 59(11):717-21. PubMed ID: 17968710
    [TBL] [Abstract][Full Text] [Related]  

  • 15. mTOR inhibitor RAD001 (everolimus) has antiangiogenic/vascular properties distinct from a VEGFR tyrosine kinase inhibitor.
    Lane HA; Wood JM; McSheehy PM; Allegrini PR; Boulay A; Brueggen J; Littlewood-Evans A; Maira SM; Martiny-Baron G; Schnell CR; Sini P; O'Reilly T
    Clin Cancer Res; 2009 Mar; 15(5):1612-22. PubMed ID: 19223496
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nordihydroguaiaretic acid (NDGA) inhibits the IGF-1 and c-erbB2/HER2/neu receptors and suppresses growth in breast cancer cells.
    Youngren JF; Gable K; Penaranda C; Maddux BA; Zavodovskaya M; Lobo M; Campbell M; Kerner J; Goldfine ID
    Breast Cancer Res Treat; 2005 Nov; 94(1):37-46. PubMed ID: 16142439
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-vascular endothelial growth factor receptor-1 antagonist antibody as a therapeutic agent for cancer.
    Wu Y; Zhong Z; Huber J; Bassi R; Finnerty B; Corcoran E; Li H; Navarro E; Balderes P; Jimenez X; Koo H; Mangalampalli VR; Ludwig DL; Tonra JR; Hicklin DJ
    Clin Cancer Res; 2006 Nov; 12(21):6573-84. PubMed ID: 17085673
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of tumor cell growth, invasion, and metastasis by EXEL-2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinases.
    Qian F; Engst S; Yamaguchi K; Yu P; Won KA; Mock L; Lou T; Tan J; Li C; Tam D; Lougheed J; Yakes FM; Bentzien F; Xu W; Zaks T; Wooster R; Greshock J; Joly AH
    Cancer Res; 2009 Oct; 69(20):8009-16. PubMed ID: 19808973
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-tumor effect of honokiol alone and in combination with other anti-cancer agents in breast cancer.
    Liu H; Zang C; Emde A; Planas-Silva MD; Rosche M; Kühnl A; Schulz CO; Elstner E; Possinger K; Eucker J
    Eur J Pharmacol; 2008 Sep; 591(1-3):43-51. PubMed ID: 18588872
    [TBL] [Abstract][Full Text] [Related]  

  • 20. AKT activity regulates the ability of mTOR inhibitors to prevent angiogenesis and VEGF expression in multiple myeloma cells.
    Frost P; Shi Y; Hoang B; Lichtenstein A
    Oncogene; 2007 Apr; 26(16):2255-62. PubMed ID: 17016437
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.